摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-ethyl-1,4,5,13-tetrahydro-5,10-dihydroxy-12-methyl-3H,15H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione | 1042921-29-8

中文名称
——
中文别名
——
英文名称
5-ethyl-1,4,5,13-tetrahydro-5,10-dihydroxy-12-methyl-3H,15H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione
英文别名
10-hydroxy-7-methylhomocamptothecin;7-methyl-10-hydroxyhomocamptothecin;20-Ethyl-7,20-dihydroxy-10-methyl-17-oxa-3,13-diazapentacyclo[11.9.0.02,11.04,9.015,21]docosa-1(22),2(11),3,5,7,9,15(21)-heptaene-14,18-dione
5-ethyl-1,4,5,13-tetrahydro-5,10-dihydroxy-12-methyl-3H,15H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione化学式
CAS
1042921-29-8
化学式
C22H20N2O5
mdl
——
分子量
392.411
InChiKey
CQYIILFNLODHHN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.7
  • 重原子数:
    29
  • 可旋转键数:
    1
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.32
  • 拓扑面积:
    100
  • 氢给体数:
    2
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Discovery of 7-Methyl-10-Hydroxyhomocamptothecins with 1,2,3-Triazole Moiety as Potent Topoisomerase I Inhibitors
    作者:Xiguo Xu、Yuelin Wu、Wenfeng Liu、Chuanquan Sheng、Jianzhong Yao、Guoqiang Dong、Kun Fang、Jin Li、Zhiliang Yu、Xiao Min、Huojun Zhang、Zhenyuan Miao、Wannian Zhang
    DOI:10.1111/cbdd.12767
    日期:2016.9
    Homocamptothecin is emerging as an important topoisomerase I inhibitor originating in natural product camptothecin. We report the modifications and SAR of homocamptothecin on position C10 to develop potent topoisomerase I inhibitors for anticancer drug discovery. Based on click chemistry, twenty‐one 1,2,3‐triazole‐substituted homocamptothecin derivatives were readily synthesized in two steps. For A549
    喜树碱是一种重要的拓扑异构酶I抑制剂,起源于喜树碱天然产物。我们报道了C10位置上喜树碱的修饰和SAR,以开发有效的拓扑异构酶I抑制剂用于抗癌药物的发现。根据点击化学,可以很容易地通过两个步骤合成二十一种1,2,3-三唑取代的同型喜树碱衍生物。对于A549,环烷基和烷基取代的化合物6j,6l和6o表现出高度的抗增殖抑制活性,IC 50值分别为30、30和50 n m。此外,环丙基6j的Topo I抑制活性高于20(S)喜树碱,表明适合进一步药物开发。
  • Trifluoromethyl-promoted homocamptothecins: Synthesis and biological activity
    作者:Lingjian Zhu、Zhenyuan Miao、Chunquan Sheng、Wei Guo、Jianzhong Yao、Wenfeng Liu、Xiaoying Che、Wenya Wang、Pengfei Cheng、Wannian Zhang
    DOI:10.1016/j.ejmech.2010.02.051
    日期:2010.7
    The homocamptothecin (hCPT) represents a new class of topoisomerase inhibitor which combines enhanced plasma stability and strong antitumor activity. Fluorine imparts desirable characteristics to drugs by modulating both the pharmacokinetics and pharmacodynamic properties of a drug. Therefore, in an attempt to improve the antitumor activity of homocamptothecins, seven new 7-trifluoromethylated homocamptothecin
    同型喜树碱(hCPT)代表一类新的拓扑异构酶抑制剂,它具有增强的血浆稳定性和强大的抗肿瘤活性。氟通过调节药物的药代动力学和药效学性质赋予药物所需的特性。因此,为了提高同型喜树碱的抗肿瘤活性,通过脯氨酸催化的弗里德兰德法制备了七个新的7-三氟甲基化的同型喜树碱衍生物。评价了在体内和体外对癌细胞系的抗肿瘤活性,以及拓扑异构酶I介导的化合物6c和8b的DNA切割的抑制特性。这些三氟甲基化的hCPT衍生物中的几种(例如6a,6b和6c)具有比拓扑替康(TPT)更高的体外抗肿瘤活性。特别地,化合物6c显示出与TPT相当的有效体内抗肿瘤活性。
  • Phosphate ester derivatives of homocamptothecin: Synthesis, solution stabilities and antitumor activities
    作者:Zhenyuan Miao、Jing Zhang、Liang You、Juan Wang、Chunquan Sheng、Jiangzhong Yao、Wannian Zhang、Hao Feng、Wei Guo、Lei Zhou、Wenfeng Liu、Linjian Zhu、Pengfei Cheng、Xiaoying Che、Wenya Wang、Chuan Luo、Yulan Xu、Guoqiang Dong
    DOI:10.1016/j.bmc.2010.03.039
    日期:2010.5
    Homocamptothecins (hCPTs) represents a new promising class of topoisomerase I inhibitors with enhanced stability and superior antitumor activity. Some phosphodiesters and phosphotriesters homocamptothecin derivatives were designed and synthesized based on our previous synthetic route. The cytotoxicity in vitro on three cancer cell lines and antitumor activity in vivo, and inhibitory properties of topoisomerase I of these derivatives were evaluated. Among them compounds 24e and 24f exhibited higher cytotoxic activity than IRT and the former exhibited the best antitumor activity in vivo and solution stability both at pH 7.4 and pH 3.0. (c) 2010 Elsevier Ltd. All rights reserved.
  • Topoisomerase I-Mediated Antiproliferative Activity of 10-Substituted and 12-Substituted Homocamptothecins
    作者:Wei Guo、Wenfeng Liu、Lingjian Zhu、Yongqiang Zhang、Pengfei Cheng、Guoqiang Dong、Chunlin Zhuang、Jianzhong Yao、Chunquan Sheng、Zhenyuan Miao、Wannian Zhang
    DOI:10.1002/cbdv.201000307
    日期:2011.8
    Homocamptothecin (hCPT) is an E‐ring modified camptothecin (CPT) analogue, which showed pronounced inhibitory activity of topoisomerase I. In search of novel hCPT‐type anticancer agents, two series of hCPT derivatives were synthesized and evaluated in vitro against three human tumor cell lines. The results indicated that the 10‐substituted hCPT derivatives had a considerably higher cytotoxic activity
    Homocamptothecin (hCPT) 是一种 E 环修饰的喜树碱 (CPT) 类似物,对拓扑异构酶 I 显示出显着的抑制活性。 为了寻找新的 hCPT 型抗癌剂,合成了两个系列的 hCPT 衍生物并在体外对三种人类肿瘤进行了评估细胞系。结果表明,10-取代的hCPT衍生物比12-取代的具有更高的细胞毒活性。在 10 个取代的化合物中,8a、8b、9b 和 9i 对肺癌细胞系 A-549 显示出与阳性对照药物拓扑替康相当甚至更强的活性。此外,hCPT 类似物 8a 和 8b 在 100 μM 的浓度下表现出比 CPT 更高的拓扑异构酶 I 抑制活性。
  • Antitumor Activities and Structure - Activity Relationship of Phosphotriester Derivatives of Homocamptothecin Based on a Semisynthetic Route
    作者:Yong-Qiang Zhang、Huo-Jun Zhang、Jing Zhang、Juan Wang、Jian-Zhong Yao、Lin-Jian Zhu、Chun-Lin Zhuang、Sheng-Zheng Wang、Guo-Qiang Dong、Chun-Quan Sheng、Zhen-Yuan Miao、Wan-Nian Zhang
    DOI:10.1071/ch11315
    日期:——

    Based on a new semisynthetic route, a series of phosphotriester 7-alkyl-homocamptothecin derivatives are designed and synthesized. Cytotoxic activity assays show that compounds 12a and 14c with a methyl in position C7 of the homocamptothecin are more potent than the other derivatives and the positive drug irinotecan against A-549, MCF-7, and LOVO cell lines. Moreover, compound 14c shows potent tumour inhibitory activity in a Colo205 xenograft model.

    基于新的半合成路线,设计并合成了一系列磷酸三酯 7-烷基高喜树碱衍生物。细胞毒活性测定显示,高喜树碱 C7 位含有甲基的化合物 12a 和 14c 对 A-549、MCF-7 和 LOVO 细胞株的毒性比其他衍生物和阳性药物伊立替康更强。此外,化合物 14c 在 Colo205 异种移植模型中显示出强大的肿瘤抑制活性。
查看更多